Nature Communications (Nov 2020)
Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer
- Birendra Kumar Sah,
- Benyan Zhang,
- Huan Zhang,
- Jian Li,
- Fei Yuan,
- Tao Ma,
- Min Shi,
- Wei Xu,
- Zhenglun Zhu,
- Wentao Liu,
- Chao Yan,
- Chen Li,
- Bingya Liu,
- Min Yan,
- Zhenggang Zhu
Affiliations
- Birendra Kumar Sah
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- Benyan Zhang
- Department of Pathology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Huan Zhang
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Jian Li
- Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Fei Yuan
- Department of Pathology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Tao Ma
- Department of Medical Oncology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Min Shi
- Department of Medical Oncology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Wei Xu
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- Zhenglun Zhu
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- Wentao Liu
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- Chao Yan
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- Chen Li
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- Bingya Liu
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- Min Yan
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- Zhenggang Zhu
- Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery
- DOI
- https://doi.org/10.1038/s41467-020-19965-6
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 8
Abstract
Neoadjuvant FLOT regimen has shown promising results for the treatment of locally advanced gastric cancer, however SOX regimen remains the preferred chemotherapy in Eastern countries. Here the authors report that the two therapies result in similar outcomes, measured as clinical downstaging and pathological response, in a phase II randomized clinical trial.
